Quick Answer
RenovoRx, Inc. reported Total Assets of $8.10 million for the year ending 2025.
- RenovoRx, Inc. showed a decrease of -0.3% in Total Assets from 2024 to 2025.
- This data is from RenovoRx, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $18.18 million | Q1 2022: $13.95 million | Q2 2022: $11.24 million | Q3 2022: $9.25 million | Q1 2023: $4.56 million | Q2 2023: $6.31 million | Q3 2023: $3.52 million | Q1 2024: $4.79 million | Q2 2024: $12.00 million | Q3 2024: $10.03 million | Q1 2025: $16.01 million | Q2 2025: $13.64 million | Q3 2025: $11.21 million.
- Over the full 6 years of available data (2020 to 2025), RenovoRx, Inc.'s Total Assets has grown by 322.9%.
- Historical annual values: Fiscal year 2025: $8.10 million | Fiscal year 2024: $8.12 million | Fiscal year 2023: $1.47 million | Fiscal year 2022: $7.27 million | Fiscal year 2021: $16.29 million | Fiscal year 2020: $1.91 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: